Scholarlink

<p>Human astroviruses (HAstVs) are a leading cause of viral gastroenteritis in children worldwide. Recently the neonatal Fc receptor (FcRn) was identified as a receptor for HAstV, however the molecular basis for the FcRn-HAstV interaction remained unclear. Here, we report the crystal structure of FcRn bound to the HAstV capsid spike domain at 3.4 angstroms resolution. We show that all classical HAstV spikes bind to FcRn and we identify three conserved HAstV spike residues that mediate binding to FcRn. Using competition binding assays, we show that the HAstV spike competes with IgG for binding to FcRn. Additionally, we demonstrate that the FcRn inhibitor, nipocalimab, and anti-HAstV neutralizing monoclonal antibodies block HAstV spike binding to FcRn, revealing their neutralization mechanisms and supporting their therapeutic potential. Overall, our findings illuminate a crucial interaction in the HAstV life cycle, which may help to inform the development of a HAstV vaccine and antibody therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Structure of the human astrovirus capsid spike in complex with the neonatal Fc receptor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Adam Lentz,
  • Sarah Lanning,
  • Khurshid R. Iranpur,
  • Lena Ricemeyer,
  • Carlos F. Arias,
  • Rebecca M. DuBois

摘要

Human astroviruses (HAstVs) are a leading cause of viral gastroenteritis in children worldwide. Recently the neonatal Fc receptor (FcRn) was identified as a receptor for HAstV, however the molecular basis for the FcRn-HAstV interaction remained unclear. Here, we report the crystal structure of FcRn bound to the HAstV capsid spike domain at 3.4 angstroms resolution. We show that all classical HAstV spikes bind to FcRn and we identify three conserved HAstV spike residues that mediate binding to FcRn. Using competition binding assays, we show that the HAstV spike competes with IgG for binding to FcRn. Additionally, we demonstrate that the FcRn inhibitor, nipocalimab, and anti-HAstV neutralizing monoclonal antibodies block HAstV spike binding to FcRn, revealing their neutralization mechanisms and supporting their therapeutic potential. Overall, our findings illuminate a crucial interaction in the HAstV life cycle, which may help to inform the development of a HAstV vaccine and antibody therapies.